Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial
First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future -...